At least two genetically distinct glucose transporters (GTs) coexist in adipose cells, one cloned from human hepatoma cells and rat brain (HepG2/brain) and another from rat skeletal muscle, heart, and adipose cells (adipose cell/muscle). Here we demonstrate differential regulation of these two GTs in adipose cells of diabetic and insulin-treated diabetic rats and compare changes in the expression of each GT with marked alterations in insulin-stimulated glucose transport activity. Adipose cell/muscle GTs detected by immunoblotting with the monoclonal antiserum 1F8 (James, D. E., R. Brown, J. Navarro, and P. F. Pilch. 1988. Nature (Lond.). 333:183-185), which reacts with the protein product of the newly cloned adipose cell/muscle GT cDNA, decrease 87% with diabetes and increase to 8.5-fold diabetic levels with insulin treatment. These changes concur qualitatively with previous detection of GTs by cytochalasin B binding and with insulin-stimulated 3-0-methylglucose transport. Northern blotting reveals that the adipose/muscle GT mRNA decreases 50% with diabetes and increases to 6.8-fold control (13-fold diabetic) levels with insulin treatment. In contrast, GTs detected with antisera to the carboxyl terminus of the HepG2 GT or to the human erythrocyte GT show no significant change with diabetes or insulin treatment. The HepG2/brain GT mRNA is unchanged with diabetes and increases threefold with insulin treatment. These results suggest that (a) altered expression of the adipose cell/ muscle GT forms the molecular basis for the dysregulated glucose transport response to insulin characteristic of diabetes, (b) the expression of two types of GTs in rat adipose cells is regulated independently, and (c) alterations in mRNA levels are only part of the mechanism for in vivo regulation of the expression of either GT species.
Introduction
Glucose transport in response to insulin is markedly impaired in adipose cells in insulin-resistant states such as diabetes (1) (2) (3) , and this may play a key role in the altered glucose homeostasis characteristic ofdiabetes. A major determinant of cellular glucose transport activity is the number of glucose transporters present in the cell; this number is dramatically altered in disease states (1) (2) (3) . Efforts to understand the regulation of glucose transporter number have been complicated by the recent demonstration that glucose transport is not mediated by a single protein species (4) (5) (6) (7) (8) (9) .' In fact, multiple glucose transporter and glucose transporter-like genes exist whose translation products are distinct due to differences in amino acid sequence (4) (5) (6) (7) (8) (9) (10) or in posttranslational modifications (1 1, 12) . It is now critical to determine how each glucose transporter is regulated and to what extent each contributes to the changes in glucose homeostasis seen in disease states.
The first glucose transporter to be cloned was obtained by screening human hepatoma (HepG2) cell (4) and rat brain (5) cDNA libraries with a polyclonal antibody directed against the human erythrocyte-facilitated diffusion glucose transporter. The resulting sequences are 98% homologous at the protein level and are presumed to represent the same glucose transporter. In both humans and rats this glucose transporter (HepG2/brain) is present in multiple non-insulin-sensitive and insulin-sensitive tissues including adipose cells (13) .' The extent to which this transporter modulates constitutive and/or insulin-stimulated glucose transport has not yet been determined. However, mRNA levels for this transporter correlate with changes in glucose transport activity and glucose transporter number in cultured cells transfected with oncogenes ( 14, 15) or treated with phorbol esters (14) . Additionally, alterations in the mRNA levels for this glucose transporter correlate with alterations in the number of glucose transporters in adipose cells from fasted and refed rats ( 16) , a model for insulin-resistant and hyperresponsive glucose transport, respectively. Transfection of this transporter into Chinese hamster ovary cells (17) and cultured 3T3-Ll adipocytes (18) has demonstrated that it participates in the stimulatory effect ofinsulin on glucose transport and it can be translocated to the plasma membrane in response to insulin. Very recently a second glucose transporter that is present in adipose cells has been cloned from rat soleus muscle (7) , adipose cells, and heart (6) . This transporter is expressed predominately in insulin-responsive tissues and shows a greater degree of translocation to the plasma membrane in adipose cells after insulin stimulation than does the HepG2/brain transporter (6) .' Evidence (6, 19) 2 suggests that it is at least 10 times as abundant in adipose cells and muscle as the HepG2/ brain glucose transporter. Hence, it could account for most of the glucose transport response to insulin in these tissues. Whereas other authors have referred to this as the insulin-regulated glucose transporter (6), we will refer to each glucose transporter species according to the tissues from which it was cloned, since other glucose transporters appear to show some insulin responsiveness (17, 18) .
The adipose cell glucose transport defect in diabetes is one of marked resistance to the acute stimulatory effect of insulin which (as measured by cytochalasin B binding) results from a depletion of cellular glucose transporters (1, 3) . Chronic insulin therapy not only reverses this resistance but brings about a transient overshoot in insulin-stimulated glucose transport to threefold control levels (20, 21) due to increases in both glucose transporter number and intrinsic activity (moles of glucose/glucose transporter per unit time). Cytochalasin B binding, a standard technique for assessing the number of glucose transporters (22), may detect multiple species ofglucose transporters in adipose cells (19, 23) . Therefore, the current study was designed to determine whether diabetes and insulin treatment of diabetes coordinately regulate the two genetically distinct species of glucose transporters identified to date in adipose cells. The relationship among distinct glucose transporter mRNA levels, glucose transporters as assessed by cytochalasin B binding and three anti-glucose transporter antisera, and glucose transport activity in adipose cells was examined. These data help to elucidate the potential functional roles of the HepG2/brain and adipose cell/muscle glucose transporters in the dysregulated glucose transport seen in disease states such as diabetes. (20) . Control rats received no treatment, as sham injections have previously been shown to have no effect on blood glucose concentrations, adipose cell size, or glucose transport activity (20) . Blood glucose was measured in whole blood using Chemstrips bG (Bio-Dynamics, Indianapolis, IN) read in an Accuchek bG reflectance meter (Bio-Dynamics).
Methods
Preparation ofisolated adipose cells and measurement ofcell size. Immediately after the animals were killed in the fed state by brief exposure to CO2 followed by decapitation, the whole epididymal fat pads were removed and isolated adipose cells were prepared by the method originally described by Rodbell (24) and subsequently modified by Cushman (25) Preparation of adipose cell subcellular membrane fractions. Subcellular membrane fractions were prepared from a minimum of eight control, 7-d diabetic, or 7-d diabetic/7-d insulin-treated rats. These time points were chosen because previous time-course studies showed maximal alterations in insulin-stimulated glucose transport and significant changes in glucose transporter number at these times (1, 20) . Isolated adipose cells were incubated at 37°C for 30 min in the presence of0 or 700 nM insulin, and samples were taken for determination of cell number and 3-0-methylglucose transport. Plasma, high density microsomal, and low density microsomal membrane fractions were prepared from the remaining cells by differential centrifugation as previously described (35) . Membrane protein was determined by the Coomassie brilliant blue method (protein assay; Bio-Rad Laboratories, Richmond, CA) described by Bradford (36) and modified by Simpson and Sonne (37) using crystalline BSA (Sigma Chemical Co.) as the standard.
Immunoblotting. Adipose cell subcellular membranes prepared as described above were subjected to 7.5 or 10% SDS-PAGE (38) and electrophoretically transferred to nitrocellulose filters. Identical membranes were used for detection of glucose transporters using three different antisera: A, a polyclonal rabbit antiserum prepared against a synthetic peptide consisting of the 16 COOH-terminal amino acids of the HepG2 and rat brain glucose transporter sequence (courtesy ofDr. Bernard Thorens, Whitehead Institute, Cambridge, MA); B, a polyclonal rabbit antiserum prepared against the purified human erythrocyte glucose transporter (courtesy ofDr. David Sogin and Dr. Peter Hinkle, Cornell University, Ithaca, NY) (39, 40) ; and C, a monoclonal antiserum, 1 F8, specific for the rat adipose cell/muscle glucose transporter (courtesy of Dr. David James, Washington University, St. Louis, MO) (6, 41) . Antisera A and C were used at 10 ,ug/ml and antiserum B at 3.3 Ag/ml. Filters were blocked with 5% nonfat dry milk, washed, and incubated with '251I-protein A (New England Nuclear, Boston, MA) after exposure to antisera A and B and with sheep anti-mouse 125I-F(ab')2 fragment (Amersham Corp., Arlington Heights, IL) after exposure to antiserum C. Dried filters were autoradiographed using XAR-5 film (Eastman Kodak Co.) and intensifying screens at -70°C. Densitometry was performed as described above.
Calculations and statistical analyses. Calculations of 3-0-methylglucose transport and adipose cell size were carried out on the Dartmouth time sharing system computer facilities. Statistical analyses were performed on the Beth Israel Hospital analyzer system using analysis of variance and the Newman-Keuls test. For densitometry data a one sample comparison test was used since these results are evaluated as a percent of control due to the arbitrary nature of OD units. Differences were accepted as significant at the P < 0.05 level.
Results
General characteristics ofrats and their tissues. Table I shows the effects on blood glucose of 7 d of diabetes and of 7 subsequent d of insulin infusion. Mean blood glucose in diabetic rats is > 22.2 mM, and insulin treatment restores blood glucose to slightly below normal. With diabetes, adipose cell size is reduced 63% and intracellular water, a reflection of intracellular protein, is reduced 41% (Table I ). 7 d ofinsulin treatment is associated with an increase in cell size although it remains 42% smaller than control, whereas intracellular water increases to 62% greater than control. These data are similar to those previously described (1, 20) . Total RNA/adipose cell does not change with diabetes, but increases to 2.4-fold control levels with 7 d of insulin treatment.
Glucose transport activity in adipose cells. The effects of 7 d of diabetes and of 7 subsequent d of insulin treatment on 3-O-methylglucose transport in isolated rat adipose cells are illustrated in Fig. 1 . Basal glucose transport activity is not significantly changed with diabetes or insulin treatment although it increases slightly with insulin treatment. In contrast, maximally insulin-stimulated activity decreases 70% from control levels with diabetes and is not only restored but increased to -300% of control levels with 7 d of insulin treatment. These results confirm our previous observations (20) which included a more detailed assessment of changes in glucose transport activity with sequential periods of diabetes and insulin treatment ranging from 1 to 35 d. Glucose transporter and actin mRNA levels in adipose cells. Both the HepG2/brain and adipose cell/muscle glucose transporter antisense RNAs hybridize under stringent conditions with a single 2.7-2.8-kb transcript in adipose cells (Fig. 2) . The size of this transcript is unaltered by diabetes or insulin treatment. When Northern blots are loaded with equivalent but arbitrary amounts of RNA per lane (Fig. 2 B) the abundance of the HepG2/brain glucose transporter mRNA is unchanged with diabetes or insulin treatment, whereas the level ofadipose cell/muscle glucose transporter decreases with diabetes and increases somewhat above control with insulin treatment. However, RNA/adipose cell (Table I) is markedly increased with insulin treatment ofthe diabetic rat. Therefore, in Fig. 2 A we have loaded quantities of RNA extracted from equivalent numbers of cells in each lane. As we discussed previously (16) this is the most physiologically relevant way of examining the data since our aim is to explain changes in glucose transport activity and glucose transporter number per cell.
Figs. 2 A and 3 A show that the amount of HepG2/brain glucose transporter mRNA expressed per cell is unchanged with diabetes but increases threefold with insulin treatment. In contrast, the level per cell of the adipose cell/muscle glucose transporter mRNA (Figs. 2 A and 3 B) decreases 50% with diabetes and increases 13-fold with insulin treatment. The level reaches 6.8-fold that of control cells (Fig. 3 B) . Actin mRNA in adipose cells is unchanged with diabetes but increases twofold over control with insulin treatment (Figs. 2 A  and 3 C) .
Immunodetection ofglucose transporters in adipose cells. The different species of glucose transporters in adipose cell subcellular membrane fractions were assessed by immunoblotting with three different anti-glucose transporter antisera.
Each antisera recognizes a protein of MAlf 43-50 kD (Fig. 4) (Fig. 4 A) and the erythrocyte glucose transporter (Fig. 4 B) a much fainter, higher molecular weight band is also seen which has previously been reported in adipose cell membranes probed with an antiserum specific for the carboxyl terminus of the HepG2/brain glucose transporter (42) . Antiserum 1F8 (Fig. 4 C) recognizes the protein product of the adipose cell/muscle glucose transporter gene (6) . In plasma membranes from basal adipose cells of diabetic rats, both the antisera against the HepG2 and the erythrocyte glucose transporters (Fig. 4, A and B ) reveal minimal change in immunodetectable glucose transporters (i.e., the amount of signal per milligram of membrane protein) compared with controls; in plasma membranes from insulin-stimulated cells there is a slight decrease of immunodetectable glucose transporters relative to control. There is a slight increase in immunodetectable glucose transporters in the low-density microsomes from adipose cells of diabetic rats, especially in the basal state.
In marked contrast, immunoblotting of the identical membranes from diabetic rat adipose cells with an antiserum to the adipose cell/muscle glucose transporter (Fig. 4 C) shows a marked reduction in the abundance of glucose transporters in both plasma membranes and low density microsomes isolated from both basal and insulin-stimulated cells.
In cells from insulin-treated diabetic rats, whether in the basal or insulin-stimulated state, antisera against the HepG2 (Fig. 4 A) and erythrocyte (Fig. 4 B) glucose transporter reveal the level of immunodetectable glucose transporters (per milligram ofprotein) to be slightly decreased in plasma membranes relative to control cells and slightly increased above control in the corresponding low density microsomes. In contrast, the level ofthe adipose cell/muscle glucose transporter (as assayed by the 1F8 antiserum) is higher in plasma membranes from insulin-treated diabetic rats, whether in the basal or insulinstimulated state, relative to control rats (Fig. 4 C) ; the level in low density microsomes is slightly decreased.
Adipose cell /muscle glucose transporter Actin Figure 2 . Detection of specific mRNA in adipose cells from control, 7-d diabetic, and 7-d diabetic/7-d insulin-treated rats by Northern gel blot analysis. Isolated cells were prepared and sampled as described in Fig. 1 Blots were hybridized with riboprobes for the glucose transporters and a random primed cDNA probe for actin as described in Methods. Autoradiograms were exposed for 3-1I d for the glucose transporters and 6 h for actin at -70°C. These blots are representative of 5-6 Northern blots performed on three separate experiments.
Previous studies measuring cytochalasin B binding in subcellular membrane fractions from diabetic rats showed a 45% decrease in the level of glucose transporters in low density microsomes in the basal state compared with control, and a 53% reduction in the number in the plasma membranes in the insulin-stimulated state (1) . In cells from insulin-treated diabetic rats, glucose transporter concentration in the low density microsomes in the basal state, measured by cytochalasin B binding, is equal to control, and in the plasma membranes in the insulin-stimulated state is -35% greater than control (20) .
The amounts ofprotein recovered in the membrane preparations used in Fig. 4 are listed in the legend to Fig. 4 , and are similar to our previous results (1, 20 A comparison between the estimated total cellular glucose transporters and levels of mRNA for each of the two glucose transporters is shown in Fig. 5 . Because glucose transporters detected with the polyclonal antiserum raised against the partially purified human erythrocyte glucose transporter (Fig. 4 B) closely correspond to those detected with the anti-HepG2 glucose transporter peptide antiserum (Fig. 4 A) , we have included only the latter data in the comparisons. The relative abundance of each species of glucose transporter per cell was estimated as previously described (35) by multiplying the OD values for immunoreactive glucose transporters per milligram of membrane protein in the plasma membranes and low density microsomes by the total amount of membrane protein in that fraction, dividing by the number of cells, and summing the values for the two fractions. For comparison, values for total cellular glucose transporters detected by cytochalasin B binding in previous studies (1, 20) were also calculated by the same technique. In those studies we demonstrated no significant change in the recoveries or cross-contamination of the membrane fractions with diabetes or insulin treatment. Glucose transporters in high density microsomes are not included in this calculation because they are generally due to contamination from the other two membrane fractions and they make up a relatively small portion of the total cellular glucose transporters (35) . In several experiments in which high density microsomal glucose transporters were included in the calculations, the same relative values for total cellular glucose transporters with diabetes and insulin treatment were obtained (data not shown).
With diabetes, the levels of both HepG2/brain glucose transporter mRNA and protein per cell are minimally different from control (Fig. 5) . After 7 d of insulin treatment of diabetic rats, the level of this transporter protein is still unaltered but the amount of mRNA increases approximately threefold. In marked contrast, the level of the adipose cell/ muscle glucose transporter decreases 87% with diabetes and the level of the corresponding mRNA falls -50%. With insulin treatment, the level of the adipose cell/muscle glucose transporter increases 8.5-fold from the diabetic levels to slightly above control levels. The level of the corresponding mRNA increases to 6.8-fold that of control and 13-fold that of the diabetic. Both with diabetes and insulin treatment the level of glucose transporters detected by cytochalasin B binding changes in parallel with that detected by the adipose cell/muscle glucose transporter antiserum. Because many assumptions are involved in these calculations (35) , these results should be interpreted cautiously and used for comparative purposes only.
Discussion
At least two genetically distinct glucose transporters are present in rat adipose cells as evidenced by Northern blot analyses and by cDNA cloning (4) (5) (6) (7) 13) .' Here we show that diabetes and its treatment with insulin differentially regulate the expression of these two glucose transporters in adipose cells. The level of the adipose cell/muscle glucose transporter protein decreases to 13% of control with diabetes and increases 8.5-fold to slightly above control levels with insulin treatment. In contrast, the level of the HepG2/brain glucose transporter is minimally altered by diabetes or by subsequent insulin treatment. These changes in transporter protein are partially but not fully paralleled by changes in the level of the corresponding transporter mRNA.
To examine the extent to which the HepG2/brain and adipose cell/muscle glucose transporters in adipose cells contribute to the changes in insulin-stimulated glucose transport with diabetes and insulin treatment, we compared the relative rates of insulin-stimulated glucose transport in intact cells with the abundance in the insulin-stimulated state of each of the glucose transporter species in the plasma membrane (Fig. 6 ). This comparison is made since only those transporters that have been recruited to the plasma membrane mediate glucose transport activity in the intact cell. Strikingly, glucose transport activity and plasma membrane glucose transporters detected by cytochalasin B binding decrease with diabetes in parallel with transporters detected by the antiserum 1F8 specific for the adipose cell/muscle glucose transporter. In contrast, there is no change in transporters detected by the anti-HepG2 glucose transporter antiserum. With insulin' treatment, glucose transport activity and plasma membrane glucose transporters detected by cytochalasin B binding increase in parallel with transporters detected by 1 F8, whereas glucose transporters detected by the HepG2 glucose transporter antiserum are again unchanged.
Preliminary data suggest that the adipose cell/muscle glu- C,ot~~~tS \4~~~Iso\\ e0 (Fig. 6 ), is consistent with previous observations that insulin treatment of the diabetic rat is also associated with an increase in glucose transporter intrinsic activity (20, 21) . The role ofthe HepG2/brain glucose transporter in normal and disease states remains to be clarified. This transporter could mediate the relatively low rate of glucose transport seen in the adipose cell in the absence of insulin. We recently showed that changes in the HepG2/brain glucose transporter mRNA correlate with changes in glucose transporter number as measured by cytochalasin B binding in adipose cells from fasted and refed rats (16) . This correlation is probably coincidental as the regulation of this glucose transporter mRNA appears to be part of a more generalized phenomenon affecting multiple mRNAs including those for several cytoskeletal and adipose cell-specific proteins. In addition, recent evidence suggests that the HepG2/brain transporter may be a small component of the glucose transporters detected by cytochalasin B binding in adipose cells ( 19, 23) . This is supported by our results (Fig. 5) In summary, we have demonstrated that two genetically distinct glucose transporters expressed in adipose cells are influenced differentially by diabetes and its treatment with insulin. The adipose cell/muscle glucose transporter appears to be the major species responsible for insulin-stimulated glucose transport in adipose cells. Its level is markedly reduced with diabetes and restored by insulin treatment, while the HepG2/ brain glucose transporter is minimally altered. This underscores the potential importance of the former transporter in the molecular basis of the insulin resistance associated with diabetes. Alterations in glucose transporter abundance are only partly explained by alterations in mRNA levels and thus posttranslational mechanisms may also contribute. These observations lay the groundwork for future studies to address the molecular mechanisms by which distinct glucose transporter species are discordantly regulated in response to changes in hormonal or metabolic states.
